Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dogwood TherapeuticsDWTX -10.92%26 Current Ratio is 3.89 as of Jun. 2026, which is 42% below its 10-year median of 6.69. GuruFocus rates DWTX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Dogwood Therapeutics ranks better than 50.11% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Dogwood Therapeutics's current ratio for the quarter that ended in Jun. 2026 was 3.89.
Dogwood Therapeutics has a current ratio of 3.89. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Dogwood Therapeutics's Current Ratio or its related term are showing as below:
DWTX'
s Current Ratio Range Over the Past 10 Years
Min: 0.03 Med: 6.69 Max: 26.23
Current: 3.89
During the past 8 years, Dogwood Therapeutics's highest Current Ratio was 26.23. The lowest was 0.03. And the median was 6.69.
DWTX's Current Ratio is ranked better than 50.11% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs DWTX: 3.89
Dogwood Therapeutics (NAS:DWTX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Dogwood Therapeutics Current Ratio Related Terms
Dogwood Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Dogwood Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DWTX vs RLYB, ALDX, ACRV: Current Ratio Comparison
For the Biotechnology subindustry, Dogwood Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dogwood Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dogwood Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Dogwood Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dogwood Therapeutics (DWTX) has a Current Ratio of 3.89 as of Jun. 2026. This is 42% below median its historical median of 6.69. Over the past decade, Dogwood Therapeutics' Current Ratio has ranged from 0.03 to 26.23. According to the industry distribution chart, Dogwood Therapeutics ranks #703 out of 1409 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Dogwood Therapeutics' Current Ratio too high?
Dogwood Therapeutics' current Current Ratio of 3.89 is 42% below median its 10-year median of 6.69. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 26.23. The Biotechnology industry median Current Ratio is 3.89. Dogwood Therapeutics' value of 3.89 is 0% at this industry median. Based on the distribution chart, Dogwood Therapeutics ranks #703 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dogwood Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Dogwood Therapeutics' Current Ratio compare to RLYB and ALDX?
According to the Biotechnology industry distribution chart, Dogwood Therapeutics ranks #703 out of 1409 companies for Current Ratio. This puts Dogwood Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.89. Dogwood Therapeutics' value of 3.89 is 0% at this benchmark. Historically, Dogwood Therapeutics' own Current Ratio has ranged from 0.03 to 26.23 over the past decade. While the company's 10-year median is 6.69 vs. the industry median of 3.89, Dogwood Therapeutics has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dogwood Therapeutics's current Current Ratio of 3.89 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dogwood Therapeutics's current Current Ratio is 3.89, which is 42% below median its own 10-year median of 6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dogwood Therapeutics stock overvalued right now?
Dogwood Therapeutics (DWTX) has a current Current Ratio of 3.89. The current Current Ratio is 3.89, which is 42% below median its 10-year median of 6.69 and 0% at the Biotechnology industry median of 3.89. Dogwood Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Dogwood Therapeutics (DWTX), the current Current Ratio is 3.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
26GF Score
Get the complete analysis for DWTX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DWTX has been successfully added to your 
